AIM:To characterize the demographic and clinical features of ethambutol optic neuropathy(EON)in an Indonesian patient population and explore prognostic factors for visual recovery.METHODS:Retrospective study of 58 EON...AIM:To characterize the demographic and clinical features of ethambutol optic neuropathy(EON)in an Indonesian patient population and explore prognostic factors for visual recovery.METHODS:Retrospective study of 58 EON patients at an Indonesian eye center(2017-2022).Demographics,ethambutol treatment,ophthalmologic findings were collected.Visual outcomes after ethambutol cessation assessed at 3-12mo.Patients categorized as having visual improvement(≥2 Snellen lines and/or>5°visual field gain)or no improvement.RESULTS:Mean age was 55.5±12.9y,with 56.9%females.Median duration of ethambutol use was 9mo(range:2-20)at a mean daily dose of 19.7±5.3 mg/kg.At presentation,mean visual acuity was 1.3 logMAR(range:0-2.5),with normal fundus appearance in 72.4%of eyes.The most common visual field defect was generalized depression(52.4%).After ethambutol cessation,56.9%of patients had visual improvement.Younger age(50.24±13.8y vs 62.14±8.9y,P<0.01),lower ethambutol dose(17.3±5 vs 23.3±2.9 mg/kg‧d,P<0.01),shorter treatment duration(6.79±2.6mo vs 10.27±1.2mo,P<0.01),and absence of hypertension(16%vs 83%,P=0.012)or kidney disease(0 vs 83%,P<0.01)were associated with higher likelihood of visual improvement.Diabetes did not differ between groups(P=0.889).CONCLUSION:Over half experience visual recovery after ethambutol cessation.Younger age,lower cumulative dose,absence of hypertension or kidney disease predict better visual outcomes.展开更多
文摘AIM:To characterize the demographic and clinical features of ethambutol optic neuropathy(EON)in an Indonesian patient population and explore prognostic factors for visual recovery.METHODS:Retrospective study of 58 EON patients at an Indonesian eye center(2017-2022).Demographics,ethambutol treatment,ophthalmologic findings were collected.Visual outcomes after ethambutol cessation assessed at 3-12mo.Patients categorized as having visual improvement(≥2 Snellen lines and/or>5°visual field gain)or no improvement.RESULTS:Mean age was 55.5±12.9y,with 56.9%females.Median duration of ethambutol use was 9mo(range:2-20)at a mean daily dose of 19.7±5.3 mg/kg.At presentation,mean visual acuity was 1.3 logMAR(range:0-2.5),with normal fundus appearance in 72.4%of eyes.The most common visual field defect was generalized depression(52.4%).After ethambutol cessation,56.9%of patients had visual improvement.Younger age(50.24±13.8y vs 62.14±8.9y,P<0.01),lower ethambutol dose(17.3±5 vs 23.3±2.9 mg/kg‧d,P<0.01),shorter treatment duration(6.79±2.6mo vs 10.27±1.2mo,P<0.01),and absence of hypertension(16%vs 83%,P=0.012)or kidney disease(0 vs 83%,P<0.01)were associated with higher likelihood of visual improvement.Diabetes did not differ between groups(P=0.889).CONCLUSION:Over half experience visual recovery after ethambutol cessation.Younger age,lower cumulative dose,absence of hypertension or kidney disease predict better visual outcomes.
